US · GLSI
Greenwich LifeSciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Stafford, TX 77477
- Website
- greenwichlifesciences.com
Price · as of 2024-12-31
$23.70
Market cap 384.05M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $29.12 | ||||
| 2021 | $20.58 | ||||
| 2022 | $12.12 | ||||
| 2023 | $15.35 | ||||
| 2024 | $12.10 |
AI valuation
Our deep-learning model estimates Greenwich LifeSciences, Inc.'s (GLSI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $23.70
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GLSI | Greenwich LifeSciences, I… | $23.70 | 384.05M | — | — | — | — | -9.97 | 62.14 | — | -9.72 | -13.23 | 62.19 | 0.00% | — | — | -341.95% | 1733.85% | -284.78% | 0.00 | — | 2.62 | 2.62 | 0.26 | 7536.00% | — | 1216.00% | -4.61% | -4.66 | 786.86% | 0.00% | 0.00% | 0.00% | -9.58 | -21.11 | — | 25.79 |
| AGEN | Agenus Inc. | $3.33 | 113.25M | +151% | -72% | — | +7,590% | -0.22 | -0.15 | 0.49 | -1.04 | — | -0.14 | -50.79% | -116.44% | -219.61% | 95.45% | 58.03% | -86.00% | -0.29 | -1.02 | 0.21 | 0.18 | -0.54 | -2298.00% | -3381.00% | -3214.00% | -314.88% | -0.72 | 76.54% | 0.00% | 0.00% | 0.00% | -0.87 | -0.66 | 1.01 | -15.68 |
| ATOS | Atossa Therapeutics, Inc. | $4.43 | 38.15M | — | — | — | — | -3.65 | 1.30 | — | -0.80 | — | 1.30 | 0.00% | — | — | -31.39% | -1873.25% | -29.54% | 0.00 | — | 14.99 | 14.31 | 2.58 | -1667.00% | — | 45.00% | -22.60% | -4.23 | -1427.53% | 0.00% | 0.00% | 0.00% | -0.80 | -1.05 | — | 7.27 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| HURA | TuHURA Biosciences, Inc. | $1.67 | 94.32M | — | — | — | — | -1.80 | 2.67 | — | -1.52 | — | 2.67 | 0.00% | — | — | -332.67% | 4773.62% | -178.25% | 0.01 | -4.26 | 3.68 | 2.42 | 0.71 | -8925.00% | — | 2291.00% | -37.91% | -2.76 | 3999.15% | 0.00% | 0.00% | 28.55% | -1.50 | -1.80 | — | -5.49 |
| IMMX | Immix Biopharma, Inc. | $8.07 | 270.94M | — | — | — | — | -1.99 | 3.24 | — | -1.17 | — | 3.24 | 0.00% | — | — | -145.76% | 1016.65% | -100.83% | 0.08 | — | 2.33 | 2.26 | 0.74 | -1461.00% | — | 3807.00% | -36.69% | -1.68 | 707.20% | 0.00% | 0.00% | 0.00% | -1.16 | -1.67 | — | -4.58 |
| IRD | Opus Genetics, Inc. | $4.16 | 286.89M | +1,572% | -90% | — | +1,569% | -0.46 | 3.97 | 2.43 | 0.06 | -0.13 | 3.97 | 100.00% | -564.72% | -523.40% | -203.19% | 512.82% | -126.71% | 0.00 | — | 3.24 | 3.20 | 0.53 | 36739.00% | -4230.00% | 220000.00% | -95.73% | -2.26 | 211.29% | 0.00% | 0.00% | 0.30% | 0.06 | 0.14 | -0.33 | -9.18 |
| ONCY | Oncolytics Biotech Inc. | $1.13 | 113.41M | — | — | — | — | -2.33 | 12.32 | — | -1.69 | — | 12.32 | 0.00% | — | — | -189.05% | 442.22% | -107.48% | 0.18 | — | 2.82 | 2.39 | 0.43 | 0.00% | — | -440.00% | -36.90% | -4.03 | 343.91% | 0.00% | 0.00% | 0.00% | -1.68 | -2.16 | — | -35.01 |
| SEER | Seer, Inc. | $1.72 | 96.75M | +1,276% | +24% | — | — | -1.41 | 0.37 | 8.76 | 0.94 | -47.63 | 0.37 | 48.99% | -717.72% | -620.91% | -23.91% | -88.56% | -21.57% | 0.08 | — | 16.53 | 15.83 | 0.16 | 296.00% | -813.00% | -2513.00% | -40.66% | -3.01 | -43.96% | 0.00% | 0.00% | 18.30% | 0.88 | 1.78 | -6.33 | 0.30 |
| SRZN | Surrozen, Inc. | $27.80 | 238.29M | — | -83% | — | — | -0.55 | -1.64 | 3.28 | -0.37 | -34.54 | -1.64 | 100.00% | -239.69% | -596.56% | -767.91% | 121.02% | -134.46% | -0.40 | — | 5.32 | 5.07 | 1.08 | 159.00% | — | -5669.00% | -50.45% | -2.41 | 83.66% | 0.00% | 0.00% | 0.00% | -0.35 | -0.50 | 0.84 | -8.68 |
| TVGN | Tevogen Bio Holdings Inc. | $0.26 | 53.24M | — | — | — | — | -12.18 | -25.05 | — | -12.85 | -0.05 | -25.05 | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | -7.18% | -1.33 | 467.53% | 0.00% | 0.00% | 55.48% | -3.15 | -14.07 | — | -89.34 |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
- CEO
- Snehal S. Patel
- Employees
- 4
- Beta
- 1.49
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $23.70) − 1 = — (DCF, example).